Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

被引：2

作者：

Santos-Garcia, Diego ^{[1
,36
]}

de Deus, Teresa ^{[2
]}

Cores, Carlos ^{[1
]}

Feal Painceiras, Maria J. ^{[1
]}

iniguez Alvarado, Maria C. ^{[1
]}

Samaniego, Lucia B. ^{[1
]}

Lopez Maside, Anton ^{[1
]}

Jesus, Silvia ^{[3
,4
]}

Cosgaya, Marina ^{[5
]}

Garcia Caldentey, Juan ^{[6
]}

Caballol, Nuria ^{[7
]}

Legarda, Ines ^{[8
]}

Hernandez-Vara, Jorge ^{[4
,9
]}

Cabo Lopez, Iria ^{[10
]}

Lopez Manzanares, Lydia ^{[11
]}

Gonzalez-Aramburu, Isabel ^{[4
,12
]}

Avila, Asuncion ^{[13
]}

Gomez-Mayordomo, Victor ^{[14
]}

Nogueira, Victor ^{[15
]}

Dotor Garcia-Soto, Julio ^{[16
]}

Borrue-Fernandez, Carmen ^{[17
]}

Solano, Berta ^{[18
]}

alvarez Sauco, Maria ^{[19
]}

Vela, Lydia ^{[20
]}

Escalante, Sonia ^{[21
]}

Cubo, Esther ^{[22
]}

Mendoza, Zebenzui ^{[23
]}

Parees, Isabel ^{[24
]}

Sanchez Alonso, Pilar ^{[25
]}

Alonso Losada, Maria G. ^{[26
]}

Lopez-Ariztegui, Nuria ^{[27
]}

Gaston, Itziar ^{[28
]}

Kulisevsky, Jaime ^{[4
,29
]}

Seijo, Manuel ^{[10
]}

Valero, Caridad ^{[30
]}

Alonso Redondo, Ruben ^{[15
]}

Buongiorno, Maria Teresa ^{[31
]}

Ordas, Carlos ^{[32
]}

Menendez-Gonzalez, Manuel ^{[33
]}

Mcafee, Darrian ^{[34
]}

Martinez-Martin, Pablo ^{[4
]}

Mir, Pablo ^{[3
,4
,35
]}

机构：

[1] CHUAC Complejo Hosp Univ A Coruna, La Coruna, Spain

[2] CHUF Complejo Hosp Univ Ferrol, La Coruna, Spain

[3] Univ Seville, Hosp Univ Virgen Rocio, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento,Inst Biomed Sevilla,C, Seville, Spain

[4] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain

[5] Hosp Clin Barcelona, Barcelona, Spain

[6] Ctr Neurol Oms 42, Palma De Mallorca, Spain

[7] Hosp Moises Broggi, Consorci Sanit Integral, Sant Joan Despi, Spain

[8] Hosp Univ Son Espases, Palma De Mallorca, Spain

[9] Hosp Univ Vall dHebron, Barcelona, Spain

[10] Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain

[11] Hosp Univ La Princesa, Madrid, Spain

[12] Hosp Univ Marques Valdecilla, IDIVAL, Santander, Spain

[13] Hosp Gen lHospitalet, Consorci Sanitari Integral, Lhospitalet De Llobregat, Barcelona, Spain

[14] Vithas Madrid La Milagrosa Univ Hosp, Vithas Hosp Grp, Inst Neurosci, Neurol Dept, Madrid, Spain

[15] Hosp Univ Lucus Augusti, Lugo, Spain

[16] Hosp Univ Virgen Macarena, Seville, Spain

[17] Hosp Infanta Sofia, Madrid, Spain

[18] Inst Assistencia Sanitaria IAS, Inst Catala Salut, Girona, Spain

[19] Hosp Gen Univ Elche, Elche, Spain

[20] Fdn Hosp Alcorcon, Madrid, Spain

[21] Hosp Tortosa Verge Cinta HTVC, Tortosa, Spain

[22] Complejo Asistencial Univ Burgos, Burgos, Spain

[23] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain

[24] Hosp Univ Ramon y Cajal, IRYCIS, Madrid, Spain

[25] Hosp Univ Puerta Hierro, Madrid, Spain

[26] Complejo Hosp Univ Vigo CHUVI, Hosp Alvaro Cunqueiro, Vigo, Spain

[27] Complejo Hosp Toledo, Toledo, Spain

[28] Complejo Hosp Navarra, Pamplona, Spain

[29] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[30] Hosp Arnau Vilanova, Valencia, Spain

[31] Hosp Univ Mutua Terrassa, Terrassa, Spain

[32] Hosp Rey Juan Carlos, Madrid, Spain

[33] Hosp Univ Cent Asturias, Oviedo, Spain

[34] Univ Maryland, Sch Med, Baltimore, MD USA

[35] Univ Seville, Fac Med, Dept Med, Seville, Spain

[36] Hosp Univ A Coruna HUAC, Complejo Hosp Univ A Coruna CHUAC, Dept Neurol, C-As Xubias 84, La Coruna 15006, Spain

来源：

MOVEMENT DISORDERS CLINICAL PRACTICE | 2024年 / 11卷 / 07期

关键词：

dyskinesia; morning akinesia; motor fluctuations; Parkinson's disease; quality of life; MOTOR COMPLICATIONS; CLINICAL-FEATURES; BODY-WEIGHT; FLUCTUATIONS; RISK; PHARMACOKINETICS; DETERMINANTS; ROPINIROLE; THERAPY; AGE;

D O I：

10.1002/mdc3.14056

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Levodopa-induced dyskinesias (LID) are frequent in Parkinson's disease (PD). Objective: To analyze the change in the frequency of LID over time, identify LID related factors, and characterize how LID impact on patients' quality of life (QoL). Patients and MethodsPD patients from the 5-year follow-up COPPADIS cohort were included. LID were defined as a non-zero score in the item "Time spent with dyskinesia" of the Unified Parkinson's Disease Rating Scale-part IV (UPDRS-IV). The UPDRS-IV was applied at baseline (V0) and annually for 5 years. The 39-item Parkinson's disease Questionnaire Summary Index (PQ-39SI) was used to asses QoL. Results: The frequency of LID at V0 in 672 PD patients (62.4 +/- 8.9 years old; 60.1% males) with a mean disease duration of 5.5 +/- 4.3 years was 18.9% (127/672) and increased progressively to 42.6% (185/434) at 5-year follow-up (V5). The frequency of disabling LID, painful LID, and morning dystonia increased from 6.9%, 3.3%, and 10.6% at V0 to 17.3%, 5.5%, and 24% at V5, respectively. Significant independent factors associated with LID (P < 0.05) were a longer disease duration and time under levodopa treatment, a higher dose of levodopa, a lower weight and dose of dopamine agonist, pain severity and the presence of motor fluctuations. LID at V0 (beta = 0.073; P = 0.027; R-2 = 0.62) and to develop disabling LID at V5 (beta = 0.088; P = 0.009; R-2 = 0.73) were independently associated with a higher score on the PDQ-39SI. Conclusion: LID are frequent in PD patients. A higher dose of levodopa and lower weight were factors associated to LID. LID significantly impact QoL.

引用

页码：830 / 849

页数：20

共 62 条

[61] Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease -: An exploratory study [J].

Zappia, M ;

Annesi, G ;

Nicoletti, G ;

Arabia, G ;

Annesi, F ;

Messina, D ;

Pugliese, P ;

Spadafora, P ;

Tarantino, P ;

Carrideo, S ;

Civitelli, D ;

De Marco, EV ;

Cirò-Candiano, IC ;

Gambardella, A ;

Quattrone, A .

ARCHIVES OF NEUROLOGY, 2005, 62 (04) :601-605

[62] Body weight influences pharmacokinetics of levodopa in Parkinson's disease [J].

Zappia, M ;

Crescibene, L ;

Arabia, G ;

Nicoletti, G ;

Bagalà, A ;

Bastone, L ;

Caracciolo, M ;

Bonavita, S ;

Di Costanzo, A ;

Scornaienchi, M ;

Gambardella, A ;

Quattrone, A .

CLINICAL NEUROPHARMACOLOGY, 2002, 25 (02) :79-82

← 1 2 3 4 5 6 7 →